Initial data on Amgen’s AMG 193 give some Tango investors a headache.

The acquisition brings closure for Mirati at last, though some investors will feel disappointed.

Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.

But a US adcom slams Amgen’s oversight of Codebreak-200, as the group’s KRAS rival Mirati surges on takeover talk.

But Repare and Black Diamond still have rebuilding to do.

After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.

And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.